Core Viewpoint - Enpro (NPO) reported quarterly earnings of $1.99 per share, exceeding the Zacks Consensus Estimate of $1.91 per share, and showing an increase from $1.57 per share a year ago, indicating a positive earnings surprise of +4.01% [1] Financial Performance - Enpro achieved revenues of $295.4 million for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 5.31%, and up from $258.4 million in the same quarter last year [2] - The company has exceeded consensus EPS estimates three times over the last four quarters and topped consensus revenue estimates four times in the same period [2] Stock Performance - Enpro shares have increased approximately 25.8% since the beginning of the year, contrasting with the S&P 500's zero return [3] Future Outlook - The company's earnings outlook is crucial for assessing future stock performance, with current consensus EPS estimates at $2.08 for the coming quarter and $8.77 for the current fiscal year [7] - The Zacks Rank for Enpro is currently 3 (Hold), indicating expected performance in line with the market in the near future [6] Industry Context - The Technology Services industry, to which Enpro belongs, is currently ranked in the bottom 45% of over 250 Zacks industries, suggesting potential challenges ahead [8]

Core Viewpoint - Expand Energy (EXE) reported quarterly earnings of $2 per share, exceeding the Zacks Consensus Estimate of $1.89 per share, and showing significant growth from $0.55 per share a year ago, indicating strong performance in the oil and gas sector [1] Financial Performance - The company achieved revenues of $2.31 billion for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 2.56%, and up from $1.6 billion in the same quarter last year [2] - Over the last four quarters, Expand Energy has exceeded consensus EPS estimates three times and topped revenue estimates two times [2] Stock Performance - Expand Energy shares have declined approximately 5.7% since the beginning of the year, contrasting with the S&P 500's slight decline of 0.1% [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the market in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $2.34 on revenues of $2.46 billion, and for the current fiscal year, it is $8.19 on revenues of $9.43 billion [7] - The trend of earnings estimate revisions for Expand Energy was mixed prior to the earnings release, which may influence future stock performance [6] Industry Context - The Alternative Energy - Other industry, to which Expand Energy belongs, is currently ranked in the bottom 36% of over 250 Zacks industries, suggesting potential challenges ahead [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could impact investor sentiment [5]

分组1 - Halozyme Therapeutics reported a quarterly loss of $0.24 per share, significantly below the Zacks Consensus Estimate of $2.15, marking an earnings surprise of -111.16% compared to earnings of $1.26 per share a year ago [1] - The company posted revenues of $451.77 million for the quarter ended December 2025, exceeding the Zacks Consensus Estimate by 0.70% and showing a year-over-year increase from $298.01 million [2] - Halozyme Therapeutics has surpassed consensus EPS estimates three times over the last four quarters and has topped consensus revenue estimates four times during the same period [2] 分组2 - The stock has increased approximately 18% since the beginning of the year, while the S&P 500 has declined by 0.1% [3] - The company's earnings outlook, including current consensus earnings expectations for upcoming quarters, will be crucial for future stock performance [4] - The current consensus EPS estimate for the next quarter is $1.66 on revenues of $366.53 million, and for the current fiscal year, it is $8.10 on revenues of $1.74 billion [7] 分组3 - The Medical - Biomedical and Genetics industry, to which Halozyme belongs, is currently ranked in the top 34% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact stock performance [5] - The estimate revisions trend for Halozyme was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6]

分组1 - Moderna reported a quarterly loss of $2.11 per share, better than the Zacks Consensus Estimate of a loss of $2.6, and an improvement from a loss of $2.5 per share a year ago, resulting in an earnings surprise of +18.75% [1] - The company achieved revenues of $678 million for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 2.81%, although this represents a decline from year-ago revenues of $966 million [2] - Moderna has outperformed the S&P 500, with shares increasing by about 36% since the beginning of the year, while the S&P 500 has declined by 0.2% [3] 分组2 - The current consensus EPS estimate for the upcoming quarter is -$2.14 on revenues of $254.87 million, and for the current fiscal year, it is -$6.70 on revenues of $2.09 billion [7] - The Medical - Biomedical and Genetics industry, to which Moderna belongs, is currently ranked in the top 34% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8]

Core Viewpoint - Atmus Filtration Technologies (ATMU) reported quarterly earnings of $0.66 per share, exceeding the Zacks Consensus Estimate of $0.57 per share, and showing an increase from $0.58 per share a year ago [1] Financial Performance - The earnings surprise for the quarter was +16.46%, with the company previously expected to post earnings of $0.61 per share but actually achieving $0.69, resulting in a surprise of +13.11% [2] - Atmus Filtration's revenues for the quarter reached $446.6 million, surpassing the Zacks Consensus Estimate by 5.75%, compared to $406.7 million in the same quarter last year [3] - The company has exceeded consensus revenue estimates three times in the last four quarters [3] Stock Performance - Atmus Filtration shares have increased approximately 19.7% since the beginning of the year, while the S&P 500 has declined by 0.2% [4] Future Outlook - The company's earnings outlook is crucial for investors, including current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [5] - The current consensus EPS estimate for the next quarter is $0.62 on revenues of $459.88 million, and for the current fiscal year, it is $2.80 on revenues of $1.89 billion [8] Industry Context - The Automotive - Original Equipment industry, to which Atmus Filtration belongs, is currently ranked in the bottom 43% of over 250 Zacks industries, indicating potential challenges ahead [9]

Core Insights - Dutch Bros (BROS) reported quarterly earnings of $0.17 per share, exceeding the Zacks Consensus Estimate of $0.10 per share, and showing an increase from $0.07 per share a year ago, resulting in an earnings surprise of +70.00% [1] - The company achieved revenues of $443.61 million for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 3.95% and up from $342.79 million year-over-year [2] Earnings Performance - Dutch Bros has consistently surpassed consensus EPS estimates over the last four quarters, indicating strong performance [2] - The company’s shares have declined approximately 12.6% since the beginning of the year, contrasting with the S&P 500's gain of 1.4% [3] Future Outlook - The future performance of Dutch Bros stock will largely depend on management's commentary during the earnings call and the earnings outlook for upcoming quarters [4][6] - Current consensus EPS estimate for the next quarter is $0.16 on revenues of $443.62 million, and for the current fiscal year, it is $0.86 on revenues of $2.03 billion [7] Industry Context - The Retail - Restaurants industry, to which Dutch Bros belongs, is currently ranked in the bottom 23% of over 250 Zacks industries, suggesting potential challenges ahead [8] - The performance of Dutch Bros may also be influenced by the overall industry outlook, as historical data shows that the top 50% of Zacks-ranked industries outperform the bottom 50% by more than 2 to 1 [8]

分组1 - DexCom reported quarterly earnings of $0.68 per share, exceeding the Zacks Consensus Estimate of $0.65 per share, and showing an increase from $0.45 per share a year ago, representing an earnings surprise of +4.62% [1] - The company achieved revenues of $1.26 billion for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 0.64% and up from $1.11 billion year-over-year [2] - DexCom has outperformed the market with a 2.7% increase in shares since the beginning of the year, compared to the S&P 500's gain of 1.4% [3] 分组2 - The current consensus EPS estimate for the upcoming quarter is $0.48 on revenues of $1.18 billion, and for the current fiscal year, it is $2.47 on revenues of $5.22 billion [7] - The Medical - Instruments industry, to which DexCom belongs, is currently ranked in the top 34% of over 250 Zacks industries, indicating a favorable outlook for the sector [8]

分组1 - Alliance Entertainment Holding Corporation reported quarterly earnings of $0.18 per share, missing the Zacks Consensus Estimate of $0.31 per share, and showing a decrease from $0.19 per share a year ago, resulting in an earnings surprise of -41.94% [1] - The company posted revenues of $368.71 million for the quarter ended December 2025, which was 8.32% below the Zacks Consensus Estimate and down from $393.67 million year-over-year [2] - Over the last four quarters, the company has surpassed consensus EPS estimates only once and has also topped consensus revenue estimates just once [2] 分组2 - The stock has underperformed the market, losing about 15% since the beginning of the year, while the S&P 500 has gained 1.4% [3] - The current consensus EPS estimate for the upcoming quarter is $0.08 on revenues of $217.43 million, and for the current fiscal year, it is $0.57 on revenues of $1.11 billion [7] - The Zacks Industry Rank indicates that the Media Conglomerates sector is in the bottom 43% of over 250 Zacks industries, suggesting potential challenges for stock performance [8]

分组1 - Legacy Education Inc. reported quarterly earnings of $0.15 per share, exceeding the Zacks Consensus Estimate of $0.13 per share, and showing an increase from $0.10 per share a year ago, resulting in an earnings surprise of +15.39% [1] - The company achieved revenues of $19.19 million for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 3.48%, and up from $13.64 million year-over-year [2] - Legacy Education Inc. has outperformed the market with a 3% increase in share price since the beginning of the year, compared to the S&P 500's gain of 1.4% [3] 分组2 - The current consensus EPS estimate for the upcoming quarter is $0.17 on revenues of $19.5 million, and for the current fiscal year, it is $0.66 on revenues of $76.6 million [7] - The Zacks Industry Rank for Schools is in the top 27% of over 250 Zacks industries, indicating a favorable outlook for the industry [8] - Legacy Education Inc. holds a Zacks Rank 3 (Hold), suggesting that the stock is expected to perform in line with the market in the near future [6]

Organon (OGN) came out with quarterly earnings of $0.63 per share, missing the Zacks Consensus Estimate of $0.73 per share. This compares to earnings of $0.9 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -13.46%. A quarter ago, it was expected that this pharmaceutical company would post earnings of $0.93 per share when it actually produced earnings of $1.01, delivering a surprise of +8.6%.Over the last four quarters, the com ...